الانتقال إلى المحتوى الرئيسي
xMedica

NCT05172960ClinicalTrials.gov

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4/X4S Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).

تدخّليةمطلوب 1,234 مشاركاً65 موقعاً4 دول

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2021-12-29; recorded start 2022-06-20
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 47 other studies in this databaseCounted from the lead sponsor named in the record (Edwards Lifesciences)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourMODERATE

A moderately rigorous design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Non-randomised allocation

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 65 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 1,234 participants (target), run at 65 sites, across 4 countries.

How this score is built
  • Enrolment31/40

    1,234 participants (target)

  • Site count21/25

    65 sites

  • Country count7/15

    4 countries

  • Planned duration10/10

    Planned over about 177 months

  • Sponsor scale6/10

    Edwards Lifesciences has led 47 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4/X4S Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).

This is a prospective, single arm, multicenter study. Subjects with bicuspid aortic valve morphology will be enrolled in a separate registry.

الحالات

  • Aortic Stenosis, Severe

الأهلية

الأهلية
الجنسالجميع
الأعمارغير مذكور في سجل السجل
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion Criteria: 1. Severe, calcific AS 2. Native aortic annulus size suitable for SAPIEN X4 THV 3. NYHA functional class ≥ II 4. The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. Exclusion Criteria: 1. Anatomical characteristics that would preclude safe femoral placement of the introducer sheath or safe passage of the delivery system 2. Aortic valve is unicuspid, bicuspid or non-calcified 3. Pre-existing mechanical or bioprosthetic valve in any position 4. Severe aortic regurgitation (\> 3+) 5. Severe mitral regurgitation (\> 3+) or ≥ moderate mitral stenosis 6. Need for mitral, tricuspid or pulmonic valve intervention within the next 12 months 7. Left ventricular ejection fraction \< 20% 8. Cardiac imaging evidence of intracardiac mass, thrombus or vegetation 9. Left ventricular outflow tract calcification that would increase the risk of annular rupture or significant PVL after THV implantation 10. Increased risk of coronary artery obstruction after THV implantation 11. Myocardial infarction within 30 days prior to the study procedure 12. Hypertrophic cardiomyopathy with subvalvular obstruction 13. Subjects with planned concomitant ablation for atrial fibrillation 14. Complex coronary artery disease (CAD) that cannot be optimally treated by percutaneous coronary intervention (PCI) 15. Any surgical or transcatheter procedure within 30 days prior to the study procedure (unless part of planned strategy for treatment of CAD). Implantation of a permanent pacemaker or implantable cardioverter defibrillator (ICD) is not considered an exclusion. 16. Any planned surgical or transcatheter intervention to be performed within 30 days following the study procedure (unless part of planned strategy for treatment of CAD) 17. Endocarditis within 180 days prior to the study procedure 18. Stroke, transient ischemic attack or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to the study procedure 19. Hemodynamic or respiratory instability requiring inotropic or mechanical support within 30 days prior to the study procedure 20. Renal insufficiency and/or renal replacement therapy 21. Leukopenia, anemia, thrombocytopenia 22. Inability to tolerate or condition precluding treatment with antithrombotic therapy 23. Hypercoagulable state or other condition that increases risk of thrombosis 24. Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with premedication 25. Subject refuses blood products 26. BMI \> 50 kg/m2 27. Estimated life expectancy \< 24 months 28. Female who is pregnant or lactating 29. Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments 30. Participating in another investigational drug or device study that has not reached its primary endpoint 31. Subject considered to be part of a vulnerable population

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةغير منطبق
التخصيصغير معشّاة
نموذج التدخّلSINGLE_GROUP
الغرض الأساسيTREATMENT
التعميةNONE (0)
التجنيدمطلوب 1,234 مشاركاً

الجهة الراعية والمتعاونون

  • Edwards Lifesciences الجهة الراعية

الأذرع والتدخلات

  • TAVR - Main CohortEXPERIMENTAL

    Subjects will undergo transcatheter aortic valve replacement (TAVR)

  • TAVR - Bicuspid RegistryEXPERIMENTAL

    Subjects with bicuspid aortic valve morphology will undergo TAVR

  • TAVR - X4S RegistryEXPERIMENTAL

    Subjects will undergo transcatheter aortic valve replacement (TAVR)

التدخلات

  • جهاز SAPIEN X4 THV

    Implantation of the SAPIEN X4 valve

  • جهاز SAPIEN X4S

    Implantation of the SAPIEN X4S valve

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Non-hierarchical composite of death and stroke

    The number of patients that died or had a stroke

    الإطار الزمني 1 year

  2. مقياس النتيجة الثانوي

    Favorable outcome per VARC-3: Composite of 1) alive, 2) Kansas City Cardiomyopathy Questionnaire (KCCQ) score ≥ 60, and 3) KCCQ score decrease ≤10 points from baseline

    The number of patients that met all of these criteria. The KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    الإطار الزمني 1 year

  3. مقياس النتيجة الثانوي

    Paravalvular leak

    Paravalvular leak will be categorized as None, Trace, Mild, Mild-Moderate, Moderate, Moderate-Severe, or Severe

    الإطار الزمني 30 days

  4. مقياس النتيجة الثانوي

    New permanent pacemaker implantation

    The number of patients with this event

    الإطار الزمني 30 days

التواريخ

التواريخ
تاريخ البدء20 يونيو 2022 (فعلي)
الإتمام الأولي1 يوليو 2027 (تقديري)
الإتمام1 يناير 2037 (تقديري)
أول نشر29 ديسمبر 2021 (فعلي)
آخر تحديث3 سبتمبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةأغسطس 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

26 موقعاً قيد التجنيد

Australia

Australia
المنشأةالمدينةالولاية أو المنطقةالحالة
Royal Adelaide HospitalAdelaideSouth Australiaنشط، دون تجنيد
The Royal Melbourne HospitalParkvilleنشط، دون تجنيد
St. Andrews War Memorial HospitalSpring HillQueenslandنشط، دون تجنيد

Canada

Canada
المنشأةالمدينةالولاية أو المنطقةالحالة
Hamilton Health ServicesHamiltonOntarioنشط، دون تجنيد
Institut Universitaire de Cardiologie et de Pneumologie de Quebec- Universite LavalQuébecQuebecنشط، دون تجنيد
St. Paul's Hospital SystemVancouverBritish Columbiaنشط، دون تجنيد

New Zealand

New Zealand
المنشأةالمدينةالولاية أو المنطقةالحالة
Christchurch HospitalChristchurchنشط، دون تجنيد

United States

United States
المنشأةالمدينةالولاية أو المنطقةالحالة
Piedmont Heart InstituteAtlantaGeorgiaنشط، دون تجنيد
Emory University AtlantaAtlantaGeorgiaنشط، دون تجنيد
Medstar Union Memorial HospitalBaltimoreMarylandقيد التجنيد
Brigham and Women's HospitalBostonMassachusettsقيد التجنيد
University at Buffalo - Kaleida HealthBuffaloNew Yorkقيد التجنيد
St. Vincent Medical Group, Inc./ St. Vincent Heart Center of Indiana, LLCCarmelIndianaنشط، دون تجنيد
Carolinas Health SystemCharlotteNorth Carolinaنشط، دون تجنيد
Novant Health and Heart Vascular InstituteCharlotteNorth Carolinaقيد التجنيد
Rush University Medical Center ChicagoChicagoIllinoisنشط، دون تجنيد
The Christ HospitalCincinnatiOhioقيد التجنيد
Kaiser PortlandClackamasOregonقيد التجنيد
The Cleveland Clinic FoundationClevelandOhioنشط، دون تجنيد
Medical City Dallas HospitalDallasTexasنشط، دون تجنيد
Baylor Heart and Vascular HospitalDallasTexasقيد التجنيد
Henry Ford HospitalDetroitMichiganنشط، دون تجنيد
Alexian Brothers Hospital NetworkElk Grove VillageIllinoisقيد التجنيد
NorthShore University HealthSystem Research Institute EvanstonEvanstonIllinoisقيد التجنيد
Northwestern University ChicagoEvanstonIllinoisقيد التجنيد
Methodist Le Bonheur HealthcareGermantownTennesseeنشط، دون تجنيد
Pinnacle Health HarrisburgHarrisburgPennsylvaniaمكتمل
Hartford HospitalHartfordConnecticutنشط، دون تجنيد
HCA Houston Healthcare Medical CenterHoustonTexasنشط، دون تجنيد
University of Texas Memorial HermannHoustonTexasنشط، دون تجنيد
University of Kansas Medical CenterKansas CityKansasنشط، دون تجنيد
Saint Luke's HospitalKansas CityMissouriنشط، دون تجنيد
Scripps Memorial Hospital La JollaLa JollaCaliforniaنشط، دون تجنيد
Dartmouth-Hitchcock Medical Center, HanoverLebanonNew Hampshireقيد التجنيد
Kaiser Los AngelesLos AngelesCaliforniaنشط، دون تجنيد
Cedars-Sinai Medical CenterLos AngelesCaliforniaقيد التجنيد
UC Health Northern Colorado (Medical Center of the Rockies)LovelandColoradoنشط، دون تجنيد
St. Patrick HospitalMissoulaMontanaنشط، دون تجنيد
Atlantic Health System MorristownMorristownNew Jerseyقيد التجنيد
Centennial Medical CenterNashvilleTennesseeقيد التجنيد
Saint Thomas HealthNashvilleTennesseeقيد التجنيد
Vanderbilt University Medical CenterNashvilleTennesseeقيد التجنيد
Rutgers Robert Wood Johnson Medical SchoolNew BrunswickNew Jerseyقيد التجنيد
Silver Cross HospitalNew LenoxIllinoisقيد التجنيد
Columbia University Medical Center/NYPHNew YorkNew Yorkقيد التجنيد
Cornell Medical CenterNew YorkNew Yorkقيد التجنيد
Montefiore Medical CenterNew YorkNew Yorkنشط، دون تجنيد
Hoag Memorial Hospital PresbyterianNewport BeachCaliforniaنشط، دون تجنيد
Sentara Norfolk General HospitalNorfolkVirginiaنشط، دون تجنيد
Naples Community Hospital Healthcare SystemNorth NaplesFloridaنشط، دون تجنيد

يُدرَج 15 موقعاً إضافياً في سجل السجل.

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

لم تُسجَّل أي تغييرات منذ أن أدرجنا هذا السجل لأول مرة.

يُسجَّل تغيير في كل مرة تحدّث فيها الجهة الراعية سجل السجل. تظهر هنا الحالة والتواريخ والتجنيد والمواقع كلما تغيّرت.